Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Zappasodi

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Immunotherapy|August 28, 2015
Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinationsRoberta Zappasodi, Taha Merghoub
Cancer Research|June 4, 2021
To Go or Not to Go?-Targeting Tregs Traveling in TumorsSanjukta Chakraborty, Roberta Zappasodi
Translational Cancer Research|October 11, 2019
Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapyRoberta Zappasodi, Taha Merghoub
Oncotarget|June 19, 2023
Targeting GITR in cancer immunotherapy - there is no perfect knowledgeDiwakar Davar, Roberta Zappasodi
Trends in Cancer|August 19, 2023
Modulating Treg stability to improve cancer immunotherapyJee Hye Kang, Roberta Zappasodi
Nature Immunology|March 4, 2022
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistanceAlexander C Huang, Roberta Zappasodi
Cancer Cell|October 10, 2018
Emerging Concepts for Immune Checkpoint Blockade-Based Combination TherapiesRoberta Zappasodi, Taha Merghoub, Jedd D Wolchok
Cancer Cell|April 11, 2018
Emerging Concepts for Immune Checkpoint Blockade-Based Combination TherapiesRoberta Zappasodi, Taha Merghoub, Jedd D Wolchok
Current Hematologic Malignancy Reports|November 9, 2018
Correction to: Strategies for Predicting Response to Checkpoint InhibitorsRoberta Zappasodi, Jedd D Wolchok, Taha Merghoub
Frontiers in Immunology|January 9, 2023
Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapyRoberta Zappasodi, Graham P Cook, Alison Taylor
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Immunotherapy|August 28, 2015
Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinationsRoberta Zappasodi, Taha Merghoub
Cancer Research|June 4, 2021
To Go or Not to Go?-Targeting Tregs Traveling in TumorsSanjukta Chakraborty, Roberta Zappasodi
Translational Cancer Research|October 11, 2019
Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapyRoberta Zappasodi, Taha Merghoub
Oncotarget|June 19, 2023
Targeting GITR in cancer immunotherapy - there is no perfect knowledgeDiwakar Davar, Roberta Zappasodi
Trends in Cancer|August 19, 2023
Modulating Treg stability to improve cancer immunotherapyJee Hye Kang, Roberta Zappasodi
Nature Immunology|March 4, 2022
A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistanceAlexander C Huang, Roberta Zappasodi
Cancer Cell|October 10, 2018
Emerging Concepts for Immune Checkpoint Blockade-Based Combination TherapiesRoberta Zappasodi, Taha Merghoub, Jedd D Wolchok
Cancer Cell|April 11, 2018
Emerging Concepts for Immune Checkpoint Blockade-Based Combination TherapiesRoberta Zappasodi, Taha Merghoub, Jedd D Wolchok
Current Hematologic Malignancy Reports|November 9, 2018
Correction to: Strategies for Predicting Response to Checkpoint InhibitorsRoberta Zappasodi, Jedd D Wolchok, Taha Merghoub
Frontiers in Immunology|January 9, 2023
Editorial: Factors determining long term anti-tumor responses to immune checkpoint blockade therapyRoberta Zappasodi, Graham P Cook, Alison Taylor
Pageof 7